Research using placebos
DOI:
https://doi.org/10.29176/2590843X.123Keywords:
Biomedical research, mycosis, placebo, beneficence, ethics committeeAbstract
We present a case based on a research project in dermatology comparing a new therapeutic proposal for the treatment of onychomycosis) with placebo.
The project was submitted for approval by the Research Ethics Committee, which did not approve it because it was considered unethical to leave patients in the placebo group without effective treatment, existing standard treatments accepted and used regularly.
The Committee proposed that the researcher could replace the placebo with one of the available treatments. The researcher accepted, but was upset by what he considered to be a rigidity of the Committee that makes it difficult to get research support from pharmaceutical companies.
An analysis of the case is made based on the ethical principles of do no harm and beneficence. The current discussion about the use of placebos in clinical research is presented.
Author Biography
José María Maya, Universidad EIA: Medellín, Antioquia, CO
Médico, magister en Salud Pública, magister en Dirección Universitaria y magister en Dirección y Gestión de la Seguridad Social; profesor titular, Universidad CES; decano general, Escuela de Ciencias de la Vida. Universidad EIA, Medellín, Colombia
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |